List of Excipients in Branded Drug VELTASSA

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Vifor Pharma Inc	VELTASSA	patiromer	53436-084	XANTHAN GUM	2027-05-29

Veltassa Excipient Strategy and Commercial Opportunities

Last updated: October 2, 2026

Veltassa is an oral potassium binder containing patiromer sorbitex calcium. Its commercial differentiation depends less on conventional inactive excipients than on the design of the patiromer polymer, calcium counterion, particle properties, flavor system, and administration platform. The strongest opportunities are lower-volume dosing, improved palatability, ready-to-use formats, pediatric delivery, and manufacturing platforms that preserve potassium-binding performance while reducing gastrointestinal burden.

What is Veltassa and how does its formulation work?

Veltassa is approved by the U.S. Food and Drug Administration for the treatment of hyperkalemia in adults and pediatric patients aged 12 years and older. It is supplied as a powder for oral suspension in single-dose packets containing 8.4 g, 16.8 g, or 25.2 g of patiromer sorbitex calcium [1].

Patiromer is a nonabsorbed cation-exchange polymer. In the gastrointestinal tract, it binds potassium in exchange for calcium. The potassium-patiromer complex is excreted in the feces. Veltassa must be administered at least three hours before or after many oral medicines because it can bind coadministered drugs in the gut [1].

The formulation has four commercially important components:

Component	Functional role	Commercial significance
Patiromer sorbitex calcium	Potassium-binding polymer and calcium source	Core performance determinant; difficult to substitute without clinical and regulatory testing
Sorbitol-containing polymer system	Supports manufacturing and product architecture	May affect gastrointestinal tolerability and dose volume
Xanthan gum	Suspending and viscosity agent	Controls dispersion and mouthfeel in the prepared suspension
Colloidal silicon dioxide	Flow and powder-processing aid	Supports packet filling and blend uniformity
Natural flavor	Palatability aid	Important for adherence, particularly in chronic and pediatric use

The patiromer polymer is the active pharmaceutical ingredient, not a conventional excipient. Excipient strategy therefore operates around the polymer’s physical properties, the counterion, suspension behavior, flavor, packaging, and alternative delivery formats.

What excipients are used in Veltassa?

The U.S. prescribing information identifies xanthan gum, colloidal silicon dioxide, and natural flavor among the formulation components [1]. The product is mixed with water or soft food before administration. It must not be taken as a dry powder.

Xanthan gum helps maintain a usable suspension after reconstitution. Its concentration affects viscosity, sedimentation, dispersion, and mouthfeel. Excessive viscosity could impair administration, while inadequate viscosity could cause rapid settling and inconsistent dosing.

Colloidal silicon dioxide supports powder flow and manufacturing control. For a multi-dose manufacturing process involving a polymeric active with distinctive particle characteristics, flowability affects packet filling, weight variation, and content uniformity.

The flavor system has a direct adherence role. Veltassa is administered chronically in patients with heart failure, chronic kidney disease, diabetes, or renin-angiotensin-aldosterone system therapy. These patients may already take multiple oral medicines. A formulation that requires mixing, has a noticeable texture, or produces an unpleasant taste can reduce persistence.

Sorbitol is also commercially relevant. Veltassa contains sorbitol associated with the patiromer sorbitex calcium material. The prescribing information warns that Veltassa is not recommended for patients with hereditary fructose intolerance because of its sorbitol content [1]. Any reformulation that reduces or removes sorbitol could broaden the addressable population, although it would require proof that potassium-binding performance and product stability remain comparable.

Which excipient attributes matter most for Veltassa?

The highest-value formulation attributes are dose volume, suspension quality, palatability, gastrointestinal tolerability, and compatibility with oral medicines.

Dose volume and polymer loading

Patiromer is administered in gram-level doses. The product’s physical dose burden creates an opportunity for higher-capacity polymers or more efficient particle engineering. A lower-mass dose with equivalent potassium binding could improve adherence and reduce the burden of mixing.

This opportunity is technically difficult. Increasing polymer capacity may alter swelling, transit, water demand, binding kinetics, and the release profile of calcium or other exchanged ions. A smaller dose is commercially attractive only if it maintains clinically meaningful potassium control.

Suspension and reconstitution

Veltassa is a powder that patients prepare before administration. Alternative excipient systems could improve wetting, reduce clumping, and maintain uniformity during the period between mixing and ingestion.

Potential approaches include:

• Improved wetting agents compatible with chronic oral use.
• Particle-size engineering to reduce floating or rapid sedimentation.
• Controlled-viscosity polymers that improve suspension without creating a thick mouthfeel.
• Granulation or agglomeration technologies that disperse more rapidly.
• Single-use liquid or semi-solid presentations.

The main risk is dose nonuniformity. A formulation that settles quickly may deliver a variable amount of patiromer if the patient does not consume the entire mixture promptly.

Flavor and mouthfeel

Flavor masking is a material commercial opportunity. The product must be mixed into water or soft food, which makes taste and texture more prominent than for tablets or capsules. A reformulation program would need to assess:

• Bitterness and aftertaste.
• Grittiness from the polymer.
• Residual flavor in water or food.
• Stability of flavors during storage.
• Compatibility with the polymer’s ion-exchange behavior.
• Use in cold and warm foods.
• Allergen and labeling requirements.

Flavor selection must not materially change hydration, polymer swelling, or potassium-binding kinetics. Sweeteners and acids can also affect taste but may create tolerability or stability issues.

What commercial opportunities exist for Veltassa excipient innovation?

1. Ready-to-use liquid Veltassa

A ready-to-use liquid could remove the need for patient reconstitution. It could improve convenience in hospitals, specialty pharmacies, long-term care facilities, and home-care settings.

The principal barriers are physical stability, microbial control, packaging weight, shelf life, and preservation of dose uniformity. A liquid product would likely require a new formulation and potentially a supplemental regulatory filing or new drug application strategy, depending on the degree of change.

2. Lower-volume powder

A higher-capacity patiromer formulation could reduce the amount of powder per dose. This would address one of the clearest adherence barriers.

Commercial value would be highest for chronic users taking the 16.8 g or 25.2 g strengths. A lower-volume product could also compete more effectively with sodium zirconium cyclosilicate, marketed as Lokelma, which is supplied as a powder for suspension but has different dosing and physicochemical characteristics [2].

3. Improved pediatric formulation

Veltassa is approved for patients aged 12 years and older. A formulation suitable for younger children could expand the market in pediatric nephrology and inherited or chronic kidney disease populations.

The relevant excipient requirements would include:

• Reduced dose volume.
• Better taste masking.
• Compatibility with soft foods.
• Clear age-based dosing.
• Lower choking and aspiration risk.
• Reduced sorbitol burden where clinically appropriate.

Pediatric development would require palatability work, age-appropriate dosing studies, and regulatory data beyond a simple excipient substitution.

4. Sprinkle or semi-solid delivery

A granulated product that can be sprinkled onto food could improve administration. This approach would need to preserve even distribution across the food portion. It would also need clear instructions because incomplete consumption could result in underdosing.

Semi-solid delivery may be particularly valuable for patients with dysphagia, enteral feeding requirements, or difficulty drinking a prepared suspension. Compatibility with feeding tubes would require dedicated testing because polymer aggregation or tube adsorption could create dose loss or obstruction.

5. Single-dose institutional packaging

Hospitals and long-term care facilities could benefit from unit-dose presentations with simplified preparation instructions. Commercial opportunities include:

• Premeasured sachets.
• Water-soluble inner packs.
• Dosing cups with fill marks.
• Integrated mixing containers.
• Barcode-enabled institutional packaging.

These changes may not require a new active ingredient, but packaging and human-factors data would remain important.

How does Veltassa compare with Lokelma and sodium polystyrene sulfonate?

Veltassa competes primarily with Lokelma and sodium polystyrene sulfonate products. The excipient and formulation strategies differ materially.

Attribute	Veltassa	Lokelma	Sodium polystyrene sulfonate
Active binding material	Patiromer sorbitex calcium	Sodium zirconium cyclosilicate	Sodium or calcium polystyrene sulfonate
Administration	Powder mixed with water or soft food	Powder mixed with water	Powder, suspension, or enema depending on product
Key counterion issue	Calcium and sorbitol-related considerations	Sodium load is clinically relevant	Sodium load and gastrointestinal safety concerns
Drug-separation instruction	Three hours from many oral medicines	Label-specific administration requirements	Product-specific
Chronic-use positioning	Strong	Strong	More limited because of safety and tolerability concerns
Excipient opportunity	Taste, volume, suspension, sorbitol reduction	Taste, sodium exposure, suspension	Safety, consistency, and tolerability

Veltassa’s commercial positioning is strongest where chronic potassium control and avoidance of sodium loading are important. Lokelma’s rapid onset and dosing flexibility create competitive pressure. Sodium polystyrene sulfonate remains a lower-cost alternative but has weaker consistency and tolerability characteristics in many chronic-use settings [1-3].

What regulatory pathway applies to Veltassa reformulation?

Veltassa is an FDA-approved drug product, not a biologic. A reformulation involving only inactive ingredients could potentially proceed through a supplemental new drug application if the sponsor can demonstrate that the change does not alter safety, efficacy, performance, or labeling requirements.

A change affecting the patiromer polymer, counterion, particle size, binding capacity, or release behavior would carry greater regulatory risk. The sponsor may need comparative dissolution or performance testing, stability data, additional clinical pharmacology work, or clinical efficacy and safety data.

An alternative product seeking approval as a generic would likely use the abbreviated new drug application pathway. Demonstrating pharmaceutical equivalence and bioequivalence may be more complex than for a conventional immediate-release tablet because patiromer is nonabsorbed and its therapeutic effect depends on local gastrointestinal ion exchange. The FDA’s product-specific requirements and reference-product designation would be central to any generic strategy [4].

Veltassa has no biosimilar pathway because patiromer is a synthetic, nonbiologic polymeric drug product.

What patent and exclusivity issues affect Veltassa?

Veltassa received FDA approval in October 2015 under NDA 207624 [5]. Its initial new chemical entity exclusivity period was separate from later patent protection. Generic entry depends on the status of Orange Book-listed patents, any pediatric exclusivity, the timing of an ANDA filing, and the outcome of Paragraph IV litigation.

The relevant risk categories are:

Risk category	Effect on commercial entry
Polymer composition patents	Can delay competing patiromer products
Manufacturing-process patents	May force a generic sponsor to design around production methods
Formulation patents	Can protect suspension, particle, flavor, or dose attributes
Method-of-use patents	May affect indications, dosing regimens, or patient populations
Orange Book listing status	Determines whether a Paragraph IV certification can trigger litigation
Regulatory exclusivity	Can delay approval independently of patent expiration
Trade secrets	May protect polymer processing, particle engineering, and scale-up know-how

A generic sponsor may avoid some formulation patents by using different excipients or manufacturing conditions. That creates a direct commercial role for excipient innovation: a new suspension system or flavor package can support a differentiated product, but it may also generate new intellectual property and regulatory complexity.

The most defensible formulation patents would typically claim a defined polymer particle distribution, a specific excipient range, improved dispersion, reduced dose volume, enhanced stability, or a measurable palatability or performance result. Broad claims directed only to common excipients would face greater validity and obviousness risk.

Which companies are positioned to challenge Veltassa?

Potential competition comes from three groups:

1. Generic pharmaceutical companies pursuing patiromer ANDA products.
2. Developers of alternative potassium binders, including sodium zirconium cyclosilicate.
3. Specialty pharmaceutical companies developing reformulated or pediatric versions.

The most credible generic challenge would likely focus on pharmaceutical equivalence, polymer characterization, manufacturing scalability, and demonstration of equivalent potassium-binding performance. A formulation challenger could avoid some Veltassa intellectual property by changing the flavor system, suspending agent, particle architecture, or packaging.

The commercial prize is meaningful because hyperkalemia is associated with chronic kidney disease, heart failure, diabetes, and use of renin-angiotensin-aldosterone system inhibitors. However, generic entry may not produce immediate substitution if prescribers value chronic-use tolerability, payer contracts, specialty distribution, or established patient adherence.

What manufacturing and intellectual-property barriers protect Veltassa?

The strongest barriers are likely to be technical rather than purely excipient-based.

Polymer production

Patiromer manufacturing requires control of polymer composition, crosslinking, particle size, residual materials, calcium loading, and sorbitol content. These parameters can affect potassium-binding capacity and product consistency.

Scale-up

A process that performs in laboratory batches may produce different swelling, flow, or particle characteristics at commercial scale. Scale-up know-how can therefore create a practical barrier even when patent claims are narrow.

Analytical testing

A competing manufacturer must characterize a nonabsorbed polymer using suitable performance assays. Conventional small-molecule dissolution tests may not adequately capture binding capacity, exchange kinetics, swelling, or behavior in gastrointestinal-like media.

Packaging

Moisture protection and dose uniformity are important for a hygroscopic or particulate polymer product. Packet materials, sealing conditions, and shipping stability can affect commercial quality.

What is the revenue exposure from Veltassa competition?

Standalone Veltassa revenue is not consistently reported in public financial disclosures, limiting precise product-level exposure analysis. The product remains strategically important within the potassium-management market because it supports chronic use in patients who may otherwise need to reduce or discontinue guideline-directed therapies.

Revenue erosion would likely occur in stages:

1. Formulary pressure and rebates before generic approval.
2. Hospital and specialty-channel substitution after an approved competitor launches.
3. Price erosion in high-volume chronic-use segments.
4. Persistence of branded demand in patients with established tolerability or specific clinical preferences.
5. Possible recovery through lower-volume, pediatric, liquid, or combination presentations.

An improved excipient platform could defend commercial value by reducing administration burden and supporting new patient segments rather than relying only on price protection.

Key Takeaways

• Veltassa contains patiromer sorbitex calcium and uses xanthan gum, colloidal silicon dioxide, and natural flavor in its oral powder formulation.
• The polymer and calcium counterion are the core technical assets; conventional excipients mainly determine suspension quality, palatability, flow, and adherence.
• The highest-value commercial opportunities are ready-to-use liquids, lower-volume doses, pediatric formulations, sprinkle products, and enteral-feeding-compatible presentations.
• Sorbitol reduction or replacement could address a labeled limitation but would require proof that potassium binding and product performance remain intact.
• Generic competition would face challenges in polymer characterization, nonabsorbed-drug equivalence, process scale-up, and formulation intellectual property.
• Veltassa competes with Lokelma and sodium polystyrene sulfonate, with differentiation based on chronic-use positioning, sodium exposure, tolerability, and administration convenience.
• Excipient patents are most defensible when linked to measurable improvements in dose uniformity, dispersion, stability, palatability, or binding performance.

FAQs

Can Veltassa be reformulated into a tablet?

A tablet presentation would be technically difficult because the product is administered at gram-level doses and the active polymer must contact gastrointestinal potassium. A compressed or encapsulated format could increase pill burden and may alter hydration, swelling, and binding kinetics.

Could a new flavor create a competing Veltassa product?

A new flavor alone would usually be a limited commercial differentiator. Its value would increase if combined with improved dispersion, lower dose volume, reduced aftertaste, or pediatric suitability. Regulatory requirements would depend on whether the change affected safety, stability, or product performance.

Is sorbitol in Veltassa an excipient or part of the active material?

Sorbitol is associated with the patiromer sorbitex calcium drug substance and contributes to the product’s composition. It is not equivalent to a simple free-sorbitol flavoring excipient. This distinction matters for formulation development, labeling, and regulatory comparability.

Does Veltassa have biosimilar competition?

No. Veltassa is a synthetic polymeric drug product, so competitors would pursue generic or alternative-drug pathways rather than biosimilar approval.

What is the most attractive Veltassa formulation opportunity?

A lower-volume, better-tasting, ready-to-use or rapidly dispersible formulation has the strongest commercial logic. It directly addresses the product’s administration burden while preserving the chronic-care use case.

References

1. U.S. Food and Drug Administration. (2024). Veltassa (patiromer) prescribing information.
2. U.S. Food and Drug Administration. (2024). Lokelma (sodium zirconium cyclosilicate) prescribing information.
3. U.S. Food and Drug Administration. (2023). Kayexalate (sodium polystyrene sulfonate) prescribing information.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. U.S. Food and Drug Administration. (2015). Approval package for NDA 207624: Veltassa.